Talal AH - Search Results

1

Virologic and immunologic effect of antiretroviral therapy on HIV-1 in gut-associated lymphoid tissue.

Talal AH, Monard S, Vesanen M, Zheng Z, Hurley A, Cao Y, Fang F, Smiley L, Johnson J, Kost R, Markowitz MH. Talal AH, et al. J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):1-7. doi: 10.1097/00126334-200101010-00001. J Acquir Immune Defic Syndr. 2001. PMID: 11176263 Clinical Trial.

2

The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.

Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, Talal A, Hurley A, Jin X, Chaudhry MR, Yaman M, Frankel S, Heath-Chiozzi M, Leonard JM, Moore JP, Racz P, Nixon DF, Ho DD. Markowitz M, et al. J Infect Dis. 1999 Mar;179(3):527-37. doi: 10.1086/314628. J Infect Dis. 1999. PMID: 9952358 Clinical Trial.

3

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD. Zhang L, et al. N Engl J Med. 1999 May 27;340(21):1605-13. doi: 10.1056/NEJM199905273402101. N Engl J Med. 1999. PMID: 10341272 Free article. Clinical Trial.

4

Effect of HIV-1 infection on lymphocyte proliferation in gut-associated lymphoid tissue.

Talal AH, Irwin CE, Dieterich DT, Yee H, Zhang L. Talal AH, et al. J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):208-17. doi: 10.1097/00042560-200103010-00002. J Acquir Immune Defic Syndr. 2001. PMID: 11242193

5

Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.

Kost RG, Hurley A, Zhang L, Vesanen M, Talal A, Furlan S, Caldwell P, Johnson J, Smiley L, Ho D, Markowitz M. Kost RG, et al. J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):332-9. doi: 10.1097/00126334-200104010-00007. J Acquir Immune Defic Syndr. 2001. PMID: 11317074 Clinical Trial.

6

The HCV and HIV coinfected patient: what have we learned about pathophysiology?

Talal AH, Canchis PW, Jacobson I. Talal AH, et al. Curr Gastroenterol Rep. 2002 Feb;4(1):15-22. doi: 10.1007/s11894-002-0033-z. Curr Gastroenterol Rep. 2002. PMID: 11825537 Review.

7

Compartmentalization of surface envelope glycoprotein of human immunodeficiency virus type 1 during acute and chronic infection.

Zhang L, Rowe L, He T, Chung C, Yu J, Yu W, Talal A, Markowitz M, Ho DD. Zhang L, et al. J Virol. 2002 Sep;76(18):9465-73. doi: 10.1128/jvi.76.18.9465-9473.2002. J Virol. 2002. PMID: 12186928 Free PMC article.

8

Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy.

Poles MA, Barsoum S, Yu W, Yu J, Sun P, Daly J, He T, Mehandru S, Talal A, Markowitz M, Hurley A, Ho D, Zhang L. Poles MA, et al. J Virol. 2003 Oct;77(19):10456-67. doi: 10.1128/jvi.77.19.10456-10467.2003. J Virol. 2003. PMID: 12970431 Free PMC article.

9

Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV.

Talal AH, Shata MT, Markatou M, Dorante G, Chadburn A, Koch R, Neumann AU, Ribeiro RM, Perelson AS. Talal AH, et al. J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):103-13. doi: 10.1097/00126334-200402010-00001. J Acquir Immune Defic Syndr. 2004. PMID: 14722440

10

Intrahepatic CD4+ cell depletion in hepatitis C virus/HIV-coinfected patients.

Canchis PW, Yee HT, Fiel MI, Dieterich DT, Liu RC, Chiriboga L, Jacobson IM, Edlin BR, Talal AH. Canchis PW, et al. Among authors: talal ah. J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1125-31. doi: 10.1097/01.qai.0000131937.52106.92. J Acquir Immune Defic Syndr. 2004. PMID: 15319671

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

138 results

Search Page